MA28039A1 - Inhibiteurs de metalloproteinases matricielles - Google Patents
Inhibiteurs de metalloproteinases matriciellesInfo
- Publication number
- MA28039A1 MA28039A1 MA28873A MA28873A MA28039A1 MA 28039 A1 MA28039 A1 MA 28039A1 MA 28873 A MA28873 A MA 28873A MA 28873 A MA28873 A MA 28873A MA 28039 A1 MA28039 A1 MA 28039A1
- Authority
- MA
- Morocco
- Prior art keywords
- alkyl
- alkylaryl
- cor
- optionally substituted
- bond
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Soft Magnetic Materials (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Lubricants (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
L'invention concerne des composés représentés par la formule (I), dans laquelle A représente une liaison, C1-6 alkyle ou CH=CH-C1-4 alkyle; B représente une liaison, O, S, SO, SO2, CO, CR7R8, CO2R14, CONR14R15, N(COR14)(COR15), N(SO2R14)(COR15) ou NR14R15; D représente une liaison ou C1-6 alkyle; E représente aryle substitué, eu hétéroaryle substitué ou non substitué; Q représente un noyau aryle ou hétéroaryle à 5 ou 6 chaînons éventuellement substitué; X représente O, S, SO, SO2. CO, CNR5, CNOR5, CNNR5R6, NR11 OU CR7R8; Y représente CR5OR11, CR5SR11, NOR5, CR5NR6R11, SO, SO2, CO, CNR5, CNOR5 ou CS; R1 and R1' représentent chacun indépendamment H, C1-6 alkyle ou C1-4 alkylaryle; R2 représente CO2R12, CH2OR12 ou CONR12R13, CONR12OR13, NR12COR13, SR12, PO(OH)2, PONHR12 ou SONHR12; R3 représente H, C1-6 alkyle ou C1-4 alkylaryle; R4 représente aryle ou hétéroaryle éventuellement substitué; Z représente une liaison, CH2, O, S, SO, SO2, NR5, OCR5R6, CR9Rl0O ou Z, R4 et Q formant ensemble un groupe tricyclique fusionné éventuellement substitué; R5 et R6 représentent chacun indépendamment H, C1-6 alkyle ou C1-4 alkylaryle; R7 et R8 représentent chacun indépendamment H, halc, C1-6 alkyle ou C1-4 alkylaryle; R9 et R10 représentent chacun indépendamment H, C1-6 alkyle éventuellement substitué par halo, cyano, OR11 ou NR6R11, C14 alkylaryle éventuellement substitué par halo, cyano, OR11 ou NR6R11, ou R9 et R10 forment un groupe hétérocyclique avec l'atome N auquel ils sont liés ; R11 représente H, C1-6 alkyle, C1-4 alkylaryle ou COR5; R12 et R13 représentent indépendamment H, C1-3 alkyle, C1-3 alkylaryle ou C1-3 alkylhétéroaryle, ou R12 et R13 forment un groupe hétérocyclique avec la fonctionnalité à laquelle ils sont liés ; R14 et R15 représentent chacun indépendamment H, C1-6 alkyle, C1-4 alkylaryle ou C1-4 alkylhétéroaryle, ou forment avec la fonctionnalité à laquelle ils sont liés un groupe hétérocyclique ou un groupe hétérocyclique fusionné. L'invention concerne aussi des dérivés physiologiquement fonctionnels de ces composés, des procédés de préparation de ceux-ci, des formulations pharmaceutiques les contenant et leur utilisation comme inhibiteurs des enzymes métalloprotéinases matricielles (MMP).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0321538.1A GB0321538D0 (en) | 2003-09-13 | 2003-09-13 | Therapeutically useful compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28039A1 true MA28039A1 (fr) | 2006-07-03 |
Family
ID=29227079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28873A MA28039A1 (fr) | 2003-09-13 | 2006-03-14 | Inhibiteurs de metalloproteinases matricielles |
Country Status (29)
Country | Link |
---|---|
US (3) | US7601729B2 (fr) |
EP (3) | EP2295408A1 (fr) |
JP (3) | JP2007505081A (fr) |
KR (3) | KR20120007566A (fr) |
CN (1) | CN1849306B (fr) |
AT (2) | ATE413384T1 (fr) |
AU (1) | AU2004272280C1 (fr) |
BR (1) | BRPI0413791A (fr) |
CA (1) | CA2538315C (fr) |
CY (1) | CY1109400T1 (fr) |
DE (2) | DE602004017622D1 (fr) |
DK (1) | DK1663970T3 (fr) |
ES (2) | ES2314436T3 (fr) |
GB (1) | GB0321538D0 (fr) |
HK (1) | HK1092141A1 (fr) |
HR (1) | HRP20080668T3 (fr) |
IL (1) | IL173305A (fr) |
IS (2) | IS2622B (fr) |
MA (1) | MA28039A1 (fr) |
MX (1) | MXPA06002458A (fr) |
NO (1) | NO20060540L (fr) |
NZ (2) | NZ573479A (fr) |
PL (1) | PL1663970T3 (fr) |
PT (1) | PT1663970E (fr) |
RU (2) | RU2370488C2 (fr) |
SG (1) | SG145685A1 (fr) |
SI (1) | SI1663970T1 (fr) |
WO (1) | WO2005026120A1 (fr) |
ZA (1) | ZA200602070B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
MX2007010185A (es) * | 2005-02-22 | 2007-12-06 | Ranbaxy Lab Ltd | Derivados de acido 5-fenil-pentanoico como inhibidores de metaloproteinasa de matriz para el tratamiento de asma y otras enfermedades. |
AU2013200728B2 (en) * | 2006-08-22 | 2014-12-18 | Sun Pharmaceutical Industries Limited | Matrix metalloproteinase inhibitors |
CN101528691B (zh) * | 2006-08-22 | 2014-11-26 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
EP2155643B1 (fr) | 2007-06-08 | 2016-08-10 | MannKind Corporation | Inhibiteurs d'ire-1a |
FR2949463B1 (fr) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | Inhibiteurs de mmp |
AU2011284397A1 (en) | 2010-07-30 | 2013-02-21 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
BR112013006932A2 (pt) | 2010-09-24 | 2016-07-12 | Ranbaxy Lab Ltd | composto composição farmacêutica e processo para preparar um composto |
WO2014083229A1 (fr) | 2012-11-28 | 2014-06-05 | Administración General De La Comunidad Autónoma De Euskadi | Utilisation d'inhibiteurs de métalloprotéases pour le traitement des maladies polykystiques hépatiques |
RU2743424C2 (ru) | 2016-02-12 | 2021-02-18 | Астеллас Фарма Инк. | Производные тетрагидроизохинолина |
CN110769866B (zh) * | 2017-06-13 | 2022-07-29 | 爱惜康有限责任公司 | 具有可控愈合的外科缝合器 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4102024A1 (de) * | 1991-01-24 | 1992-07-30 | Thomae Gmbh Dr K | Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
WO1995029901A1 (fr) * | 1994-04-28 | 1995-11-09 | Uniroyal Chemical Company, Inc. | Derives azoles fongicides |
EE9800172A (et) * | 1995-12-06 | 1998-12-15 | Astra Pharmaceuticals Limited | Ühendid |
JP4008033B2 (ja) | 1996-04-19 | 2007-11-14 | ナームローゼ・フエンノートチヤツプ・オルガノン | 置換ベンジルアミン及びうつ病の治療のためのその使用 |
MY132470A (en) * | 1996-05-15 | 2007-10-31 | Bayer Corp | Substituted oxobutyric acids as matrix metalloprotease inhibitors |
US6242616B1 (en) | 1996-12-03 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
US6870058B2 (en) | 1996-12-03 | 2005-03-22 | The Trustees Of The University Of Pennsylvania | Compounds which mimic the chemical and biological properties of discodermolide |
US20050065353A1 (en) | 1996-12-03 | 2005-03-24 | Smith Amos B. | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof |
US5789605A (en) | 1996-12-03 | 1998-08-04 | Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof |
US6096904A (en) | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
US5804581A (en) * | 1997-05-15 | 1998-09-08 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
US6608052B2 (en) * | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
EP1381594A1 (fr) * | 2001-04-13 | 2004-01-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Composes d'uree utilises en tant qu'agents anti-inflammatoires |
US7102008B2 (en) * | 2002-08-01 | 2006-09-05 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
EP1575911B1 (fr) * | 2002-11-19 | 2010-01-13 | Galderma Research & Development | Nouveaux composes biaromatiques qui activent les recepteurs du type ppar-gamma et leur utilisation dans les compositions cosmetiques et pharmaceutiques |
GB0312654D0 (en) * | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
MX2007010185A (es) | 2005-02-22 | 2007-12-06 | Ranbaxy Lab Ltd | Derivados de acido 5-fenil-pentanoico como inhibidores de metaloproteinasa de matriz para el tratamiento de asma y otras enfermedades. |
CN101528691B (zh) | 2006-08-22 | 2014-11-26 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
-
2003
- 2003-09-13 GB GBGB0321538.1A patent/GB0321538D0/en not_active Ceased
-
2004
- 2004-09-10 RU RU2006106850/04A patent/RU2370488C2/ru not_active IP Right Cessation
- 2004-09-10 JP JP2006525794A patent/JP2007505081A/ja active Pending
- 2004-09-10 ES ES04765231T patent/ES2314436T3/es active Active
- 2004-09-10 PL PL04765231T patent/PL1663970T3/pl unknown
- 2004-09-10 NZ NZ573479A patent/NZ573479A/en not_active IP Right Cessation
- 2004-09-10 ES ES08163972T patent/ES2362954T3/es active Active
- 2004-09-10 PT PT04765231T patent/PT1663970E/pt unknown
- 2004-09-10 EP EP10176905A patent/EP2295408A1/fr not_active Withdrawn
- 2004-09-10 KR KR1020127000264A patent/KR20120007566A/ko not_active Application Discontinuation
- 2004-09-10 AU AU2004272280A patent/AU2004272280C1/en not_active Ceased
- 2004-09-10 AT AT04765231T patent/ATE413384T1/de active
- 2004-09-10 WO PCT/EP2004/010319 patent/WO2005026120A1/fr active Application Filing
- 2004-09-10 CA CA2538315A patent/CA2538315C/fr not_active Expired - Fee Related
- 2004-09-10 EP EP04765231A patent/EP1663970B1/fr active Active
- 2004-09-10 DE DE602004017622T patent/DE602004017622D1/de active Active
- 2004-09-10 BR BRPI0413791-4A patent/BRPI0413791A/pt not_active IP Right Cessation
- 2004-09-10 SG SG200805432-2A patent/SG145685A1/en unknown
- 2004-09-10 DE DE602004031991T patent/DE602004031991D1/de active Active
- 2004-09-10 KR KR1020137014317A patent/KR20130079628A/ko not_active Application Discontinuation
- 2004-09-10 SI SI200431008T patent/SI1663970T1/sl unknown
- 2004-09-10 MX MXPA06002458A patent/MXPA06002458A/es active IP Right Grant
- 2004-09-10 CN CN200480026229.7A patent/CN1849306B/zh not_active Expired - Fee Related
- 2004-09-10 EP EP08163972A patent/EP2042488B1/fr active Active
- 2004-09-10 KR KR1020067005114A patent/KR20060120648A/ko active Search and Examination
- 2004-09-10 NZ NZ545211A patent/NZ545211A/en not_active IP Right Cessation
- 2004-09-10 US US10/571,443 patent/US7601729B2/en not_active Expired - Fee Related
- 2004-09-10 AT AT08163972T patent/ATE502922T1/de not_active IP Right Cessation
- 2004-09-10 DK DK04765231T patent/DK1663970T3/da active
-
2006
- 2006-01-23 IL IL173305A patent/IL173305A/en not_active IP Right Cessation
- 2006-01-26 IS IS8268A patent/IS2622B/is unknown
- 2006-02-02 NO NO20060540A patent/NO20060540L/no not_active Application Discontinuation
- 2006-03-10 ZA ZA200602070A patent/ZA200602070B/en unknown
- 2006-03-14 MA MA28873A patent/MA28039A1/fr unknown
- 2006-11-15 HK HK06112572.5A patent/HK1092141A1/xx not_active IP Right Cessation
-
2008
- 2008-11-07 US US12/266,767 patent/US8263602B2/en not_active Expired - Fee Related
- 2008-11-26 RU RU2008146479/04A patent/RU2008146479A/ru not_active Application Discontinuation
- 2008-12-19 HR HR20080668T patent/HRP20080668T3/xx unknown
-
2009
- 2009-01-27 CY CY20091100090T patent/CY1109400T1/el unknown
- 2009-08-19 IS IS8843A patent/IS8843A/is unknown
- 2009-09-01 US US12/551,892 patent/US8343986B2/en not_active Expired - Fee Related
-
2011
- 2011-06-14 JP JP2011132261A patent/JP2011231118A/ja not_active Withdrawn
-
2012
- 2012-01-25 JP JP2012012663A patent/JP2012107031A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28039A1 (fr) | Inhibiteurs de metalloproteinases matricielles | |
ATE362910T1 (de) | Matrix metalloprotease inhibitoren | |
BR0201697A (pt) | Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos | |
SE8008680L (sv) | Basiska etrar, sett for deras framstellning och farmaceutiska beredningar innehallande dem | |
EA200100090A2 (ru) | Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции | |
HUP0201475A2 (hu) | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
BG106847A (en) | Substituted piperazine derivatives as mtp inhibitors | |
DK1010698T3 (da) | Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem | |
ATE239021T1 (de) | Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
BR0307776A (pt) | Derivados de ácidos aminados, o respectivo processo de preparo e as composições farmacêuticas que os contêm | |
EA200301079A1 (ru) | Терапевтическое средство по поводу повышенной чувствительности мочевого пузыря | |
DK1188752T3 (da) | Fremgangsmåde til fremstilling af substitueret alkylaminderivat | |
DK0401125T3 (da) | Biphenylderivater, fremgangsmåde til fremstilling af disse samt mellemprodukter derfor | |
PT955310E (pt) | Novos derivados do acido (3,4,7,8,9,10)-hexa-hidro-6,10-dioxo-6h-piridazino[1,2-a] [1,2]diazepina-1-carboxilico, seu metodo de preaparacaoe sua aplicacao na preparacao de medicamentos | |
BR0101466A (pt) | Compostos de ciclobutaindolcarboxamida,processo para a sua preparação e composiçõesfarmacêuticas contendo os mesmos | |
GB1183442A (fr) |